86 related articles for article (PubMed ID: 20386531)
1. Updates on therapeutic approaches in HER2-positive disease.
Dickler MN
Clin Adv Hematol Oncol; 2010 Feb; 8(2):105-7. PubMed ID: 20386531
[No Abstract] [Full Text] [Related]
2. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
3. Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D
Clin Adv Hematol Oncol; 2007 Jun; 5(6):456-8. PubMed ID: 17679920
[No Abstract] [Full Text] [Related]
4. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
5. Ten years of HER2-directed therapy: still questions after all these years.
Krop IE; Winer EP
Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
[No Abstract] [Full Text] [Related]
6. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.
Valachis A; Nearchou A; Lind P; Mauri D
Breast Cancer Res Treat; 2012 Oct; 135(3):655-62. PubMed ID: 22875745
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
11. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Baselga J
Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
[No Abstract] [Full Text] [Related]
12. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
13. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
[No Abstract] [Full Text] [Related]
14. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
15. Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.
Metzger-Filho O; Vora T; Awada A
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S31-9. PubMed ID: 20374028
[TBL] [Abstract][Full Text] [Related]
16. Overcoming treatment challenges in advanced breast cancer.
Harkins B; Geyer CE
Semin Oncol Nurs; 2007 Nov; 23(4 Suppl 2):S10-6. PubMed ID: 18054677
[TBL] [Abstract][Full Text] [Related]
17. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].
Liao N; Zhang GC; Li XR; Yao M; Wang K
Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):943-5. PubMed ID: 19460715
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
[No Abstract] [Full Text] [Related]
19. Genentech's anticancer Mab expected by November.
Robertson D
Nat Biotechnol; 1998 Jul; 16(7):615. PubMed ID: 9661186
[No Abstract] [Full Text] [Related]
20. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]